Dry Eye

Increased pressure and inflammation require prompt treatment to avoid complications.

The collaboration agreement will allow the two companies to find a potential new treatment for chronic dry eye disease.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Focusing on the care of patients with MGD, Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO, provide key takeaways on treatment practices.

Dry eye experts provide comprehensive insights on the role of in-office procedural therapies.

Selina McGee, OD, FAAO, discusses the role of cyclosporine ophthalmic solution (VEVYE) in the treatment of dry eye disease.

Experts provide clinical insights on the first FDA-approved treatment for evaporative dry eye, perfluorohexyloctane ophthalmic solution (MEIBO).

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO, discuss the first-line treatment of MGD, highlighting factors that inform treatment selection.

Experts on dry eye describe the potential long-term consequences for patients if MGD is left untreated.

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.

Dry eye specialists provide detailed insights on the differences between aqueous-deficient and evaporative dry eye disease.

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO, provide an overview of meibomian gland dysfunction (MGD) and its causes.

Perfluorohexyloctane may slow evaporation to reduce dry eye.

Exploring strategies for effective management of a multifaceted condition.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The solution, CAM360 AmnioGraft, is hydrated and shelf-stable without need for refrigeration.

The trial, in part of the ASTRO study, will evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment 0.5%.

One of the resources provided by the partnership is a Dry Eye Wheel, which provides mitigation, measurement, and management processes to inform the treatment of dry eye disease.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The novel therapy for dry eye is a cross-linked hyaluronic acid derivative cleared by the FDA.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

The rabbit model found that the levels of the active metabolites were very comparable, whether or not eyes had received a prior installation of perfluorohexyloctane.